GoAI
Get started
Insmed Incorporated logo

Insmed Incorporated

INSM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$125.77

+$0.69 · +0.55%

Aug 21, 4:00 PM ET

INSM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

53

Fair Value

Momentum

37

Weakening

Sentiment

65

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
William H. Lewis
Listed since
Jun 1, 2000
Employees
1,664

Market position

Day range

Current $125.77

52-week range

Current $125.77

Open
$125.22
Previous close
$125.08
Volume
1.12M
0.32× average
Average volume
3.49M
Average daily volume
Market cap
27.26B USD
Beta
0.79
Market reference 1
50-day average
$110.8
+13.51% above average
200-day average
$144.18
-12.77% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
37.44B USD
P/E (TTM)
-30.6×
P/B (TTM)
36.09×
P/S (TTM)
23.96×
EV / EBITDA
-31.96×
Earnings yield
-3.43%
Free cash flow yield
-2.60%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
83.27%
Operating margin
-71.86%
Net margin
-76.94%
Return on equity
-172.78%
Return on assets
-56.38%
Return on invested capital
-64.84%

Financial health

Debt / equity
0.77×
Current ratio
3.83×
Altman Z-score
8.27
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends112%-20%-152%-284%Gross margin, FY2021: 76.57%Gross margin, FY2022: 77.53%Gross margin, FY2023: 78.52%Gross margin, FY2024: 76.43%Gross margin, FY2025: 79.41%Operating margin, FY2021: -199.03%Operating margin, FY2022: -186.39%Operating margin, FY2023: -232.51%Operating margin, FY2024: -241.47%Operating margin, FY2025: -194.04%Net margin, FY2021: -230.63%Net margin, FY2022: -196.26%Net margin, FY2023: -245.59%Net margin, FY2024: -251.24%Net margin, FY2025: -210.54%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 76.57%. Gross margin FY2022 77.53%. Gross margin FY2023 78.52%. Gross margin FY2024 76.43%. Gross margin FY2025 79.41%. Operating margin FY2021 -199.03%. Operating margin FY2022 -186.39%. Operating margin FY2023 -232.51%. Operating margin FY2024 -241.47%. Operating margin FY2025 -194.04%. Net margin FY2021 -230.63%. Net margin FY2022 -196.26%. Net margin FY2023 -245.59%. Net margin FY2024 -251.24%. Net margin FY2025 -210.54%.

Income trends

Revenue

606.42M USD+66.73%

Operating income

−1.18B USD-33.99%

Net income

−1.28B USD-39.73%
Income trends across reported periods794.74M USD41.46M USD−711.82M USD−1.47B USDRevenue, FY2021: 188.46M USDRevenue, FY2022: 245.36M USDRevenue, FY2023: 305.21M USDRevenue, FY2024: 363.71M USDRevenue, FY2025: 606.42M USDOperating income, FY2021: −375.09M USDOperating income, FY2022: −457.32M USDOperating income, FY2023: −709.63M USDOperating income, FY2024: −878.25M USDOperating income, FY2025: −1.18B USDNet income, FY2021: −434.65M USDNet income, FY2022: −481.53M USDNet income, FY2023: −749.57M USDNet income, FY2024: −913.77M USDNet income, FY2025: −1.28B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 188.46M USD. Revenue FY2022 245.36M USD. Revenue FY2023 305.21M USD. Revenue FY2024 363.71M USD. Revenue FY2025 606.42M USD. Operating income FY2021 −375.09M USD. Operating income FY2022 −457.32M USD. Operating income FY2023 −709.63M USD. Operating income FY2024 −878.25M USD. Operating income FY2025 −1.18B USD. Net income FY2021 −434.65M USD. Net income FY2022 −481.53M USD. Net income FY2023 −749.57M USD. Net income FY2024 −913.77M USD. Net income FY2025 −1.28B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue606.42M USD363.71M USD305.21M USD245.36M USD188.46M USD
Cost of goods sold124.88M USD85.74M USD65.57M USD55.13M USD44.15M USD
Gross profit481.55M USD277.97M USD239.64M USD190.23M USD144.31M USD
Research and development771.09M USD598.37M USD571.01M USD397.52M USD272.74M USD
Selling, general, and administrative701.17M USD461.12M USD344.5M USD265.78M USD234.27M USD
Operating expenses1.66B USD1.16B USD949.26M USD647.55M USD519.4M USD
Interest income60.66M USD53.31M USD42.13M USD11.08M USD174K USD
Interest expense83.8M USD84.91M USD81.69M USD26.45M USD40.47M USD
Depreciation and amortization16.45M USD11.01M USD10.58M USD10.33M USD14.18M USD
Operating income−1.18B USD−878.25M USD−709.63M USD−457.32M USD−375.09M USD
Net income−1.28B USD−913.77M USD−749.57M USD−481.53M USD−434.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-6.72%
11 comparable reports
Latest EPS result
-0.06
Estimate -0.67 · Beat by 91.08%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-0.66-1.27-1.89Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual -1.32, estimate -1.17, surprise -12.82%, Miss. Q2 2025, reported May 8, 2025: actual -1.42, estimate -1.34, surprise -5.97%, Miss. Q3 2025, reported Aug 7, 2025: actual -1.7, estimate -1.3, surprise -30.77%, Miss. Q4 2025, reported Oct 30, 2025: actual -1.75, estimate -1.33, surprise -31.58%, Miss. Q1 2026, reported Feb 19, 2026: actual -1.54, estimate -1.07, surprise -43.93%, Miss. Q2 2026, reported May 7, 2026: actual -0.76, estimate -0.963, surprise +21.11%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.06, estimate -0.672, surprise +91.08%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate -0.37, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates534M381.92M229.83M77.75MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 104.44M USD, estimate 102.08M USD, surprise +2.31%, Beat. Q2 2025, reported May 8, 2025: actual 92.82M USD, estimate 91.47M USD, surprise +1.48%, Beat. Q3 2025, reported Aug 7, 2025: actual 107.42M USD, estimate 104.13M USD, surprise +3.16%, Beat. Q4 2025, reported Oct 30, 2025: actual 142.34M USD, estimate 115.45M USD, surprise +23.30%, Beat. Q1 2026, reported Feb 19, 2026: actual 263.84M USD, estimate 231.25M USD, surprise +14.10%, Beat. Q2 2026, reported May 7, 2026: actual 305.96M USD, estimate 300.81M USD, surprise +1.71%, Beat. Q3 2026, reported Aug 6, 2026: actual 425.49M USD, estimate 395.5M USD, surprise +7.58%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 501.22M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$196.85

56.52% upside
Past 12 months12-month forecastHigh $235Average $196.85Low $169

Rating distribution

35 ratings
Strong buy00%
Buy3394%
Hold13%
Sell13%
Strong sell00%

Recent analyst actions

12 institutions
Roth CapitalmaintainBuy

INSM news

seekingalpha.com

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors.…

Read source
benzinga.com

Biotech Is Booming, But These 2 Stocks Missed the Memo

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDAQ:IBB) jumped nearly 5% Wednesday and pushed to new all-time highs, according to data from Benzinga Pro.

Read source
zacks.com

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.

Read source
marketbeat.com

Insmed Q2 Earnings Call Highlights

Insmed NASDAQ: INSM reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and increasing its long-term…

Read source
seekingalpha.com

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 3, 2011

1:10

Stock split

Effective Jul 31, 2000

1:4

INSM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INSM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
680.97M
Weight
0.03%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
246.21M
Weight
0.26%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
245.54M
Weight
0.13%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Mid-Cap ETF logoVanguard Morningstar Mid-Cap ETFVO
Market value
231.26M
Weight
0.10%
AUM
224.7B USD
Expense ratio
0.03%
Price / 1D
$82.97+0.53%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
200.78M
Weight
1.89%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Morningstar Growth ETF logoVanguard Morningstar Growth ETFVUG
Market value
176.64M
Weight
0.05%
AUM
372B USD
Expense ratio
0.03%
Price / 1D
$87.50+0.38%
iShares Russell Mid-Cap Growth ETF logoiShares Russell Mid-Cap Growth ETFIWP
Market value
154.65M
Weight
0.76%
AUM
20.62B USD
Expense ratio
0.23%
Price / 1D
$143.66+0.99%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
142.24M
Weight
0.32%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%

Continue in GoAI

Research INSM

research.disclaimer